- Home
- INCR vs EPIX Comparison
INCR vs EPIX Comparison
Compare INCR & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- EPIX
- Stock Information
- Founded
- INCR 1994
- EPIX 2009
- Country
- INCR Israel
- EPIX Canada
- Employees
- INCR N/A
- EPIX N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- EPIX Health Care
- Exchange
- INCR Nasdaq
- EPIX Nasdaq
- Market Cap
- INCR 65.3M
- EPIX 73.5M
- IPO Year
- INCR N/A
- EPIX N/A
- Fundamental
- Price
- INCR $1.46
- EPIX $1.65
- Analyst Decision
- INCR
- EPIX Hold
- Analyst Count
- INCR 0
- EPIX 3
- Target Price
- INCR N/A
- EPIX $2.00
- AVG Volume (30 Days)
- INCR 29.6K
- EPIX 286.3K
- Earning Date
- INCR 12-24-2024
- EPIX 02-11-2025
- Dividend Yield
- INCR N/A
- EPIX N/A
- EPS Growth
- INCR N/A
- EPIX N/A
- EPS
- INCR N/A
- EPIX N/A
- Revenue
- INCR $72,420,918.00
- EPIX N/A
- Revenue This Year
- INCR N/A
- EPIX N/A
- Revenue Next Year
- INCR $39.30
- EPIX N/A
- P/E Ratio
- INCR N/A
- EPIX N/A
- Revenue Growth
- INCR N/A
- EPIX N/A
- 52 Week Low
- INCR $1.17
- EPIX $1.40
- 52 Week High
- INCR $3.72
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- INCR 52.10
- EPIX 25.75
- Support Level
- INCR $1.30
- EPIX $1.63
- Resistance Level
- INCR $1.47
- EPIX $1.74
- Average True Range (ATR)
- INCR 0.05
- EPIX 0.06
- MACD
- INCR 0.02
- EPIX 0.10
- Stochastic Oscillator
- INCR 88.83
- EPIX 12.82
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.